Dutch start-up VectorY Therapeutics has been given the green light by the FDA for a phase 1/2 trial of a drug against a target implicated in up to 97% of amyotrophic lateral sclerosis (ALS) cases. VTx ...
Introduction Perinatal depression poses substantial risks to both mothers and their offspring. Given its chronic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results